Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
erythromycin + bromhexine
- Development stage
- Unknown
- Lead developer
- Boffin Biotech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Erycad (also marketed as Erycad B-250) is a fixed-dose combination tablet containing the macrolide antibiotic erythromycin and the mucolytic agent bromhexine hydrochloride. Developed and manufactured by Boffin Biotech under its Cadini Pharma division, this combination is indicated for the treatment of respiratory tract infections, such as bronchitis and pneumonia, where bacterial infection is accompanied by excessive or viscous mucus. Erythromycin acts by binding to the 50S ribosomal subunit of susceptible bacteria, thereby inhibiting protein synthesis, while bromhexine hydrochloride acts as a mucolytic agent by depolymerizing mucopolysaccharide fibers to reduce mucus viscosity and facilitate expectoration.
- Brand names
- Ericad B 250ErycadErycad B 250Erycad B-250
- Other names
- erythromycin + bromhexine hydrochloride
02
Targets
Bacterial 50S ribosomal subunitTMPRSS2 (Transmembrane protease serine 2)
Beyond the preview
Go deeper on erythromycin + bromhexine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on erythromycin + bromhexine.